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This paper is a personal account on the discovery and characterization of the 5-HT2C 
receptor (first known as the 5-HT1C receptor) over 30 years ago and how it translated into 
a number of unsuspected features for a G-protein coupled receptor (GPCR) and a 
diversity of clinical applications. The 5-HT2C receptor is one of the most intriguing 
members of the GPCR superfamily. Initially referred to as 5-HT1CR, the 5-HT2CR was 
discovered while studying the pharmacological features and the distribution of 
[3H]mesulergine labelled sites, primarily in the brain using radioligand binding and slice 
autoradiography. Mesulergine (SDZ CU-085), was at the time best defined as a ligand 
with serotonergic and dopaminergic properties. Autoradiographic studies showed 
remarkably strong [3H]mesulergine-labelling to the rat choroid plexus. [3H]mesulergine-
labelled sites had pharmacological properties different from at the time known or 
purported 5-HT receptors. In spite of similarities with 5-HT2 binding, the new binding site 
was called 5-HT1C, because of its very high affinity for 5-HT itself. Within the following ten 
years, the 5-HT1CR (later named 5-HT2C) was extensively characterized 
pharmacologically, anatomically and functionally:  it was one of the first 5-HT receptors to 
be sequenced and cloned. The 5-HT2CR is a G protein coupled receptor (GPCR), with a 
very complex gene structure. It constitutes a rarity in the GPCR family: many 5-HT2CR 
variants exist, especially in humans, due to RNA editing, in addition to a few 5-HT2CR 
splice variants. Intense research led to therapeutically active 5-HT2C receptor ligands, 
both antagonists (or inverse agonists) and agonists: keeping in mind that a number of 
antidepressants and antipsychotics are 5-HT2CR antagonists/inverse agonists. 
Agomelatine, a 5-HT2CR antagonist is registered for the treatment of major depression. 
The agonist Lorcaserin is registered for the treatment of aspects of obesity and has 
further potential in addiction, especially nicotine/ smoking. There is good evidence that the 
5-HT2CR is involved in spinal cord injury-induced spasms of the lower limbs, which can be 
treated with 5-HT2CR antagonists/inverse agonists such as cyproheptadine or SB206553. 
The 5-HT2CR may play a role in schizophrenia and epilepsy. Vabicaserin, a 5-HT2CR 
agonist has been in development for the treatment of schizophrenia and obesity, but was 
stopped. As is common, there is potential for further indications for 5-HT2CR ligands, as 
suggested by a number of preclinical and/or genome wide association studies (GWAS) on 
depression, suicide, sexual dysfunction, addictions and obesity. The 5-HT2CR is clearly 
affected by a number of established antidepressants/ antipsychotics, and may be one of 
the culprits in antipsychotic-induced weight gain. 
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THE EARLY DAYS: 1983-1988. 5-HT1C/2C RECEPTORS CONTRIBUTE TO 5-HT 
RECEPTOR SUBTYPE AWARENESS: 
The discovery of 5-HT2C receptor took place more than 30 years ago, in the middle of a 
revolutionary period of change in receptor pharmacology (see Lefkowitz, 2004; Palacios 
et al. 2010). The realization that single entities such as neurotransmitters or hormones 
were acting through a multiplicity of receptors, which can each take additional forms either 
by splice or editing variants as is the case for the 5-HT2C receptor was “new”, and as 
discovered later, became even more complex, with the notion of variable constitutive 
activity and eventually differential coupling or signalling bias. The concept of receptors 
was initially postulated in the early 1900’s by Paul Ehrlich as “selected binding sites for 
chemotherapeutic agents” and evolved further as JN Langley formulated the concept of 
“receptive substances” (see, Bennett 2000).  
For much of the 20th century, receptors were defined in functional assays based on 
responses collected in isolated tissues to chemical series and translated in 
pharmacological effects in animal models and from there extended to the therapeutic use 
of such new molecular entities. This concept is the basis for the development of still about 
half of the current therapeutic targets and for the discovery of innumerable drugs. 
Despite many decades of receptor pharmacology and related drug discovery, the 
existence of receptors as actual molecular entities was still debated in the 70’s. The 
introduction of radioligand binding and affinity labelling which led to the solubilization and 
purification of receptor proteins, e.g. in the labs of Jean Pierre Changeux and Robert 
Lefkowitz, (see Lefkowitz 2004) opened the “molecular era of receptor research” and to 
the cloning of the first receptors: i.e. the cholinergic nicotinic and the  adrenergic 
receptors which represent the two big families of receptors, i.e. ligand-gated channels and 
GPCRs. These discoveries led ultimately to Nobel Prizes for the discovery of GPCRs and 
their structure by Brian Kobilka and Robert Lefkowitz (Chemistry, 2012). Earlier, the Nobel 
Committee, whether in Physiology/Medicine or Chemistry, recognized the discovery of 
odorant receptors (Richard Axel and Linda Buck, 2004), the transmitters activating these 
receptors and playing multiple roles in disease, such as acetylcholine, noradrenaline, 
dopamine and serotonin or neuropeptides (Sir Bernard Katz, Ulf von Euler and Julius 
Axelrod, 1970) (Roger Guillemin, Andrew Schally and Rosalyn Yalow, 1977) (Arvid 
Carlsson, Paul Greengard and Eric Kandel, 2000), the prostaglandins (Sune Bergstrom, 
Bengt Samuelsson, Sir John Vane, 1982), drugs acting through these receptor (Sir James 
Black, Gertrude Elion and George Hitchings, 1988), signaling molecules such as cAMP 
(Earl Sutherland, 1971) and NO/cGMP (Robert Furchgott, Louis Ignarro and Ferid Murad, 
1998) or the role of G proteins in GPCRs (Alfred Gilman and Martin Rodbell, 1994). 
The development of rapid and simple techniques using radiolabeled ligands (radioligands) 
to identify receptors in cell-free preparations pioneered by Changeux, Lefkowitz and 
others, opened new possibilities to study receptors. Radioligand binding was expanded 
later to intact tissue sections for the localization of receptors in situ at the light microscope 
level and eventually to whole body imaging in vivo. The combination of these two 
methods, in addition to second messenger studies and in situ hybridization, constituted 
the workhorse of much of our work for the next 10 years, until recombinant technologies 
allowed to investigate cloned receptors. These methodologies revealed many unexpected 
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features of drug and neurotransmitter receptors. One, which raised tremendous 
opposition in the beginning, was the multiplicity of receptors for a single neurotransmitter. 
It was generally considered that the number of receptors for a given neurotransmitter 
should be limited (to 1 or 2), and some of the resistance to change was nearly dogmatic. 
From the extreme: “one transmitter-one receptor” to the “liberal”: “one transmitter-two 
receptors”. Examples: acetylcholine-nicotinic and muscarinic, noradrenaline-alpha and 
beta adrenergic receptors, histamine-H1 and H2, metabotropic vs ionotropic receptors 
(e.g. this duality was accepted for acetylcholine, but much less so for 5-HT or GABA 
receptors). Proposing more than two receptors for a single neurotransmitter was 
considered non practical by some, heretical by others, and if the proposal was based on 
radioligand binding, and/or second messengers / electrophysiology, doubly heretical. In 
other words, radioligand binding was a rather obscure side product of biochemical 
pharmacology, especially if combined with second messenger studies and/or 
electrophysiology. Along the same lines, the effects of guanine nucleotides on agonist 
binding (Laduron 1983), were merely considered as detergent-like effects of GTP and the 
likes, rather than on active vs. inactive states of the receptor (a few years later in 1994, 
the Nobel Prize was awarded for the discovery of G-Proteins, see above). However 
results were accumulating making it difficult to artificially constrain the size of receptor 
families. 
With respect to serotonin, 2 receptors were considered to be optimal in 1983/1984, when 
we started collaborating on this subject: José María Palacios (JMP), Angel Pazos (AP) 
and Danny Hoyer (DH). The receptor molecular biology era was only to start a few years 
later with successful cloning of the beta2 receptor. There was an interesting twist: by 
homology screening, the cloning of the beta2 receptor lead to that of G21 /5-HT1A receptor 
and then to the beta1 receptor.  This was not surprising as 5-HT1A receptors have high 
affinity for beta blockers such as pindolol, as revealed in our binding studies, and of 
course 5-HT and beta receptors share structural homologies (see Wang et al. 2013; 
Wacker et al. 2013). Thus in the brain, one would distinguish between 5-HT1 and 5-HT2 
binding sites (Peroutka and Snyder 1979), labelled by [3H]5-HT and [3H]spiperone or 
[3H]ketanserin, respectively; keeping in mind that [3H]LSD would label both. In the guinea 
pig ileum, 5-HT-M and 5-HT-D receptors had been known since the mid 1950’s (the 
effects of 5-HT on receptors were first reported in the gastro intestinal tract), but there 
were no binding studies in the GI tract, primarily since this was the field of physiologists 
and electro-physiologists (Gaddum and Picarelli 1957; Bradley et al. 1986; Hoyer et al. 
1994). It was becoming clear that 5-HT2 sites and 5-HT-D receptors were very closely 
related, if not overlapping (Engel et al. 1984). This lead to reconsider the whole 
nomenclature. In 1984, there was agreement to name these receptors “5-HT1-like”, 5-HT2 
(5-HT-D) and 5-HT3 (5-HT-M). The Bradley scheme was born and the first receptor 
nomenclature group was in its infancy (Bradley et al. 1986). The 5-HT4 receptor had 
already been recognised by Pramod Saxena and colleagues, but it was not an integral 
part of the new nomenclature, neither were subtypes of 5-HT1 or 5-HT2 receptors.  There 
had been at times confusion between 5-HT3, 5-HT4 and 5-HTM, receptors, not surprisingly 
since the tools/ligands used to characterise these receptors were still in their infancy 
(Hoyer, 1989) and these receptors were primarily investigated in the guinea pig ileum. 
The ileum is extremely complex, since most known 5-HT receptors are expressed 
functionally in the gut, although the proportions, localisation and distribution of the various 
receptors change along the alimentary tract and vary across species.  
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[3H]-Mesulergine: A Dopamine D2 Receptor Ligand That Defines A New 5-HT 
Binding Site. 
The discovery of the 5-HT1C (later 5-HT2C) receptor took place at Sandoz (now Novartis) 
in Basel, Switzerland. Sandoz had a long tradition of working with ergot derivatives with 
multiple useful pharmacological activities. Semi-synthetic ergot compounds had been 
developed over the many years in many therapeutic areas, with famous scientists such as 
Stoll and Hoffman who discovered many ergot alkaloids and eventually LSD in the 1920-
1940s (see Giger and Engel 2006). One of the later ergoline-like compounds was CU-
32085, also known as mesulergine. It presented interesting dopaminomimetic activities in 
animal models and was being developed as an anti-parkinsonian drug (Markstein 1983; 
Enz et al. 1984). Radioligand binding studies with [3H]mesulergine were carried out by Dr. 
Annemarie Closse. Somewhat surprisingly given its dopaminergic profile, [3H]mesulergine 
showed high affinity binding to 5-HT2 receptors in the rat brain (Closse 1983).  It must 
however be kept in mind that a number of these ergolines like [3H]LSD and [125I]LSD, 
have high affinity for both 5-HT1 and 5-HT2 receptors, and we will see later that [125I]LSD 
does indeed label 5-HT2C receptors. In 1983, having just set up receptor autoradiography 
developed in Michael Kuhar’s laboratory at Johns Hopkins University to label brain tissue 
sections with radioligands and study brain receptor distribution and pharmacology, JMP 
decided to investigate the localization and nature of [3H]mesulergine binding sites in the 
brain of various species. Thus, rat brain sections were incubated with [3H]mesulergine to 
generate autoradiograms. When the films were developed, there was disappointment: at 
first glance the film appeared “empty”, as it happens when exposure is short. Similar 
stories get repeated: when we did the first 5-HT3 receptor autoradiographic studies with 
[3H]ICS-205930, exposure time reached 5.5 months (!) before we could detect relevant 
binding in the brain (Waeber et al. 1988). A closer look though, revealed that 
[3H]mesulergine labelled some dark lines which did not correspond to any known 
neuronal structures or nuclei, namely the choroid plexus. This binding was selectively 
blocked by co-incubation with low concentrations of “cold” 5-HT. We knew from our own 
experience that [3H]5-HT also labelled intensely the choroid plexus, as well as many other 
brain areas, but no special attention had been paid to the choroid plexus, as it was not a 
target for CNS research: for transporters and brain penetration yes, but not for the study 
of future drug targets in the general field of neurology or psychiatry.  
Thus, while one could expect some 5-HT2 binding as well as dopamine D2 binding with 
[3H]mesulergine, our first studies were pointing to a very different pattern. Competition 
studies suggested that we had identified a “new 5-HT-related site”. Preliminary 
autoradiographic data were further confirmed by AP, a postdoctoral fellow who had just 
joined JMP’s team.  
These results were first presented at a meeting of the British Pharmacological Society in 
1984 in Birmingham and were received with amused comments from established 
researchers in the field. This coincided with the first nomenclature group to meet and 
agree on the existence and naming of “5-HT1-like”, 5-HT2 and 5-HT3 receptors; the group 
convened by Professor Philipp Bradley, precisely in Birmingham (Bradley et al. 1986).  
A full description of the pharmacological profile and characteristics of the 5-HT1C receptor 
was published in 1984, and their detailed anatomical distribution, compared to 5-HT1A and 
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5-HT1B and 5-HT2 receptors, was published a year later. Those studies have been cited 
extensively (Pazos et al. 1984a; Pazos and Palacios 1985; Pazos et al. 1985), as of today 
661, 1395 and 899 times respectively.  
Characterization Of 5-HT1C Binding Sites In Pig Choroid Plexus:  
Classical membrane radioligand binding studies are a simple way to study the kinetic 
features as well as to fully characterize the pharmacological profile of a new binding site 
with a large number of drugs. In 1983, high throughput screening did not yet exist, and 
testing 3 Mio compounds in 2.5 days using fluorescent imaging plate readers (FLIPR®) 
sounded like science fiction. Pipetting was done by hand, the reaction was carried out in 
12.5ml tubes incubated in water baths at 37 C, each tube filtered individually, and each 
filter placed by hand into another large vial which then needed about 10 ml of scintillation 
fluid, all introduced single handedly into scintillation counters: no 96, 384 or 1536 plates, 
fed and handled by robots! DH had just joined Sandoz in 1983 following his postdoctoral 
training in Perry Molinoff´s lab (U of Pennsylvania). His PhD thesis dealt with the 
discovery and development of two highly utilised radioligands for the study of alpha1 
([125I]BE-2254 also known as [125I]HEAT) and beta-adrenoceptors ([125I]ICYP, which will be 
used later to characterize 5-HT1B receptors). Thus, radioligand binding was used 
massively in the characterization of 5-HT1C/2C  and other 5-HT receptors in a variety of 
species. In order to characterize the pharmacological profile of a new binding site, one 
needs a source of tissue rich in the sites of interest, that can be easily obtained and in 
sufficient amounts. Since the putative new 5-HT receptor had been initially identified in 
the choroid plexus, (we later demonstrated its presence in other brain regions), we 
decided to study its pharmacology by using radioligand binding in choroid plexus 
membrane preparations.  The rat choroid plexus is small and in order to save animal 
numbers and costs, we turned to the pig plexus. It was indeed cheaper to collect brains 
from the local slaughterhouse. To obtain a homogeneous choroid plexus membrane 
preparation was not trivial, since the plexus is primarily a tight mix of vessels and harsh 
connective tissue. Eventually, we managed to obtain acceptable membrane fractions, 
allowing to perform regular radioligand binding studies with adequate quality (Pazos et al. 
1984a, 1984b; Hoyer et al. 1985a, 1985b). Parallel autoradiographic studies were carried 
out to define the brain distribution of what was to become the 5-HT2C receptor in various 
species (see below).  
Thus, we compared the profiles of [3H]mesulergine, [3H]5-HT and [3H]LSD labelled sites in 
choroid plexus membranes. The very first studies with [3H]mesulergine added an 
additional surprise. We found that mesulergine had a unique binding profile in the choroid 
plexus, different from its pharmacology in the rest of the brain. In addition, species 
differences in the pharmacology of [3H]mesulergine binding became evident, a new 
feature in receptor studies, adding further complexity to the field. A few years later, it was 
recognized that such differences are real and dictated by the gene structure of these 
receptors (Hoyer and Middlemiss 1989; Hartig et al. 1996). In essence, human and pig 
receptors were different from rodent receptors, and we struggled with designing 
appropriate experiments as well as “selling” the new concept to management, since 
rodents were/are very commonly used in drug development. 
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In rat cortex, [3H]mesulergine- and [3H]ketanserin-labelled sites were indistinguishable 
(thus classical 5-HT2 binding); in contrast, porcine and human cortex [3H]mesulergine 
binding sites were pharmacologically distinct from [3H]ketanserin-labelled sites, in other 
words the rank orders of affinity of a great number of compounds although close were 
clearly different. On the other hand, in the choroid plexus of the three species, 
[3H]mesulergine-, [3H]5-HT- and [3H]LSD- labelled sites were highly similar, yet different 
from 5-HT2 binding e.g. those labelled by [3H]ketanserin. [3H]mesulergine binding sites in 
the choroid plexus were named 5-HT1C, as our results clearly demonstrated that they 
were distinct from the 5-HT1A and 5-HT1B binding sites, the latter two were well 
characterized as separate entities at that time in our labs.  5-HT1C sites had low to very 
low affinity for a range a “classical” 5-HT2 ligands such as ketanserin, spiperone, 
cinanserin or pirenperone, and high affinity for 5-HT. Further, 5-HT1C sites were labelled 
by [3H]5-HT, the prototypical 5-HT1 radioligand. As more receptor families were 
characterised, it became clear that high affinity [3H]5-HT binding was by no means 
specific for the 5-HT1 family, but this was one the agreed features of 5-HT1-like receptors 
at the time preceding receptor cloning (Hoyer et al. 1994). 
5-HT Receptor Autoradiography: The Power Of Anatomical Resolution 
In parallel to the studies carried out in membranes, we performed a detailed 
autoradiographic characterization of the whole suite of 5-HT binding sites, first in the 
brain, later in peripheral tissues.  We did also compare various species, since we were 
primarily interested in human pharmacology, yet needed to know about the pharmacology 
of the commonly used laboratory animals.  We were not interested in developing rodent 
selective drug candidates. Studies were first designed to identify brain areas specially 
enriched in the different proposed subtypes of 5-HT1 receptors, in order to reinforce the 
specificity of 5-HT1C sites as a separate entity from the other 5-HT sites/receptors. At that 
time, 5-HT1 binding was divided into 5-HT1A and 5-HT1B (Pedigo et al. 1981).  8-OH-DPAT 
had just been reported as a 5-HT1A selective agonist (Hjorth et al. 1982; Gozlan et al. 
1983; Middlemiss and Fozard 1983). [3H]8-OH-DPAT was shown to label a more 
restricted population of sites in the brain than [3H]5-HT (Pazos and Palacios 1985; Hoyer 
et al. 1986b). We used [3H]-5-HT, [3H]-mesulergine, other radioligands and 8-OH-DPAT, 
SDZ 21-009, (a very useful beta blocker picked by Guenter Engel), and mesulergine itself 
as the main competing ligands. We identified anatomical areas particularly enriched in 
each of the 5-HT1 and 5-HT2 receptor subtypes: the dentate gyrus of the hippocampus for 
5-HT1A, the substantia nigra for 5-HT1B and, of course, the choroid plexus for the “new” 5-
HT1C site. These studies contributed to establish a clear separation between 5-HT1C, 5-
HT1A and 5-HT1B sites both in terms of pharmacological profile and brain localisation. We 
also characterized the pharmacological profile of the new receptor at the microscopic 
level, by constructing autoradiographic competition curves: these studies revealed a 
pharmacological profile fully comparable to the one found in membranes (see below). 
They also revealed the first picture of the distribution of this subtype throughout the rat 
brain: the choroid plexus presented, by far, the highest binding density, but clearly 
detectable levels of 5-HT1C sites were found over the olfactory system, hippocampus 
(CA1 field), thalamic nuclei, substantia nigra and spinal cord (external); lower levels were 
detected in neocortex (piriform, cingulate, frontal), putamen, globus pallidus, 
hypothalamus (ventromedial) and nuclei of the brainstem (i.e., spinal trigeminal nucleus). 
The autoradiographic studies highlighted the true power of combining the anatomical 
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dimension to the classical membrane binding strategies: without the initial identification of 
a region enriched in one class of receptors, it would have been rather unlikely to perform 
the detailed studies in choroid plexus membranes that eventually led to the full description 
of the finally re-named 5-HT2C receptors. Again, the choroid plexus as opposed to 
hippocampus or cortex or striatum is not a brain region that would be commonly studied, 
and in fact is rather difficult to process; almost like performing binding in blood vessel 
preparations.  Later we also used antibodies to localise the new receptor, although one 
must confess that anti GPCR antibodies have led to a lot of dubious data (Abramowski et 
al.  1995). 
Further Characterisation Of 5-HT1 And 5-HT2 Sites 
We subsequently showed (Hoyer et al. 1985b) that brain 5-HT1/[3H]5-HT binding could be 
displaced in a tri-phasic manner by the beta blocker SDZ 21-009: high affinity for 5-HT1B 
sites, intermediate for 5-HT1A and very low affinity for 5-HT1C sites. Our autoradiographic 
data had also demonstrated the ability of this compound to selectively bind to 5-HT1B sites 
in specific brain areas (Hoyer et al. 1985a; 1985b). Some further indole beta blockers 
turned out to be very important tools for the delineation of 5-HT1 receptor subtypes. 
Indeed, we noticed that [125I]ICYP ([125I]iodocyanopindolol), a very potent antagonist at β-
adrenoceptors, which is still the most popular radioligand for labelling these receptors 
(Engel et al. 1981; Hoyer et al. 1982), was also labelling brain sites sensitive to 5-HT and 
other serotoninergic ligands. Although, the radioligand was initially described as highly 
specific for beta receptors, we had to admit that it was perfectly suitable to label 5-HT1B 
receptors in rodents.  But not in other species, certainly not in pigs or primates, or rabbits; 
again highlighting species differences. 
Using an iterative process, we put bits and pieces together comparing the binding profiles 
of radioligands known to interact with 5-HT/Dopamine D1-D2/5-HT2 or mixed 5-HT2/D2, 
beta receptor ligands, and the one that seems to label pretty much everything, [3H]LSD 
and its derivative [125I]LSD (Hoyer et al. 1986c). Incidentally, [125I]SCH23982 a “selective” 
dopamine D1 ligand, and [125I]LSD were found to label 5-HT1C sites in the choroid plexus 
(Hoyer and Karpf 1988). We also used [3H]8-OH-DPAT which at the time was (and still is) 
an exquisite tool to define 5-HT1A sites, whereas [3H]ketanserin turned out to be another 
valuable tool for labelling 5-HT2 receptors. Both membrane binding and autoradiographic 
studies allowed to define the pharmacological profile / rank order of affinities on the new 
receptor, with the drugs available at that time.  In addition to 5-HT and mesulergine, LSD, 
methysergide and mianserin showed high or very high affinity for 5-HT1C receptors; 
ketanserin, pirenperone and methergine bound to the new site with an intermediate 
affinity; by contrast, 8-OH-DPAT, (-) SDZ 21-009 and spiperone had low or very low 
affinity for 5-HT1C receptors. 
The iterations were multiple: radioligand binding was performed in brain membranes, 
including choroid plexus, receptor autoradiography in brain slices of various species, and 
functional models such as contractions of the guinea-pig ileum (Engel et al. 1984; 
Kalkman et al. 1986), inhibition of 5-HT release in the cerebral cortex (Engel et al. 1986), 
stimulation or inhibition of cAMP production in hippocampus  (Markstein et al. 1986;  
Schoeftter et al. 1989), in the substantia nigra (Hoyer and Schoeffter 1988; Schoeffter et 
al. 1988; Schoeftter and Hoyer 1989; Schoeffter et al. 1989), stimulation of PLC 
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production in choroid plexus (Hoyer et al. 1989) or in smooth muscle cells, contraction or 
relaxation of various blood vessels (Kalkman et al. 1984; 1986; Doyle et al. 1986; Hoyer 
1988a, 1998b; Schoeffter et al. 1989) and in vivo (Kalkman et al. 1984; Doods et al.  
1988). 
5-HT Receptor Binding And Autoradiography In The Human Brain 
After characterizing the properties of the new site in animal brain (mouse, rat, guinea-pig, 
pig, bovine and many others), we went on with the characterization and localization of 5-
HT1C receptors in postmortem human brain tissue. Taking advantage of the fact that Dr. 
Alphonse Probst, a pathologist at the University of Basel, shared a collaboration with the 
JMP group aimed to visualize and analyse neurotransmitter receptors in human tissue, 
we applied similar experimental procedures both in membranes and sections from a 
series of human brains, although confronting the specific limitations associated to the 
work with postmortem material. By the end of 1985 the anatomical distribution and 
pharmacological profile of 5-HT1 and 5-HT2 receptors in the human brain were obtained, 
proving to be relatively similar to that reported in animals (choroid plexus starring again). 
However species differences were highlighted again: the marked differences in 5-HT1B 
pharmacology complicated for quite a while the exact delineation of the distribution of 5-
HT1C sites in non-choroid plexus areas (Pazos et al. 1987a; 1987b; Hoyer et al. 1986a, 
1986b). The high density of 5-HT1C receptors in the choroid plexus of all the species 
investigated was calling for an examination of their potential functional role in the volume 
and composition of cerebrospinal fluid. We cannulated rat cerebral ventricles and using 
perfusion with artificial CSF and radiolabeled inulin, examined alterations in the volume of 
CSF. We found effects of 5-HT and other drugs, but the system was too complex to carry 
out detailed studies and we did not progress enough to publish. However, Lindvall-
Axelsson et al (1998) performed a detailed study in the rabbit, a better suited model, 
reporting inhibition of CSF production by 5-HT which was blocked by ketanserin.  
In Situ Hybridization Complements Autoradiography: 
The cloning of 5-HT1C/2C receptor (see below) allowed for the visualization of mRNA 
coding for this receptor by in situ hybridization histochemistry in brain: 5-HT1C/2C binding 
and mRNA distributions were largely overlapping in mammalian brain (Hofman and 
Mezey 1989; Palacios et al. 1990; Mengod et al. 1990; Pompeiano et al. 1994; Lopez-
Gimenez et al. 2001; Serrats et al. 2005; Mengod et al. 2010). There is the occasional 
mismatch as has been reported for other GPCRs.  For instance, high levels of mRNA are 
found in the habenular nucleus, whereas binding levels are low. The monkey brain was 
then studied extensively:  5-HT2C mRNA is present in choroid plexus, in layer V of most 
cortical regions, in nucleus accumbens, ventral anterior caudate and putamen, septal 
nuclei, diagonal band, ventral striatum, and extended amygdala (López-Giménez et al. 
2001). Several thalamic, midbrain, and brainstem nuclei also express 5-HT2C mRNA.  In 
general, [3H]mesulergine binding and mRNA showed a good correlation across the brain, 
in agreement with a somatodendritic localization of 5-HT2C receptors. When there was 
lack of correlation, this was compatible a possible location on axon terminals,  such as in 
the septal nuclei and horizontal limb of the diagonal band (presence of mRNA with 
apparent absence of binding sites) and interpeduncular nucleus (presence of binding sites 
with apparent absence of mRNA). 5-HT2C receptors are also present in the spinal cord 
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(see below). There has been no evidence for 5-HT2C binding or mRNA in peripheral 
tissues.  
The 5-HT1C Receptor Defines A New 5-HT Receptor Family 
It became clear that 5-HT2 receptors were acting via the PLC/PKC/Calcium pathway, 
whereas 5-HT1 receptors were negatively modulating cAMP production (Hoyer 1988a). 
There was no evidence for cAMP modulation in the choroid plexus (Palacios et al. 1986), 
whereas stimulation of PLC activity had a 5-HT1C profile (Conn and Sanders Bush 1986; 
Conn et al. 1986; Hoyer et al. 1989). We also suggested that 5-HT1C receptors were 
present in the stomach fundus, and attempted to correlate both activities (5-HT1C binding 
and 5-HT-mediated contraction), with little success. Further, the 5-HT2B receptor is 
expressed in the fundus (Foguet et al. 1992a; 1992b) and there is no evidence that 5-
HT1C receptors are expressed in the periphery. With the tools available at the time, a 
pharmacologic differentiation between the two receptors was not easy. Right from the 
beginning, the pharmacological similarity between 5-HT1C and the classical 5-HT2 
receptors in terms of pharmacological profile was rather striking. We thus suggested 
these receptors to be closely linked (Hoyer 1988a) as confirmed subsequently.  
POST 1988.  THE CLONING OF 5-HT RECEPTORS: 5-HT1C BECOMES 5-HT2C.  
The 5-HT1C receptor, one of the first of the 5-HT family, was cloned before the 5-HT2 
receptor (Lubbert et al. 1987), although the full length 5-HT1C sequence came somewhat 
later. The 5-HT1C gene has a rather complex structure (Julius et al. 1988; Saltzman et al. 
1991; Yu et al. 1991; Milatovich et al. 1992; Stam et al. 1994). The 5-HT2 receptor was 
cloned in close succession (Pritchett et al. 1988; Julius et al. 1989; Foguet al. 1992a; 
1992b). The 5-HT2 receptor family was then extended, when the fundus receptor was 
sequenced and cloned, named first 5-HT2F, (for fundus), to become 5-HT2B. Together, 
these three receptors showed some marked sequence similarities (Julius et al. 1989; 
Foguet et al. 1992b) and thus formed a group structurally distinct from the 5-HT1R family, 
which eventually expanded to 5-HT1B/1D, 5-ht1e and 5-HT1F (Hoyer et al.1994; Hartig et al. 
1996). 
Logically, the serotonin receptor nomenclature committee agreed that subtypes existed 
for 5-HT1 and 5-HT2 receptors (cloning had strongly supported these views): it was then 
decided to place the 5-HT1C receptor within the 5-HT2 family.  Thus, 5-HT1C was re-named 
5-HT2C, which was the least disruptive move (Humphrey et al. 1993; Hoyer et al. 1994) 
and the 5-HT1C spot remains unassigned.  
The availability of recombinant receptors in homogeneous cell population allowed for 
relatively selective 5-HT2C receptor agonists and antagonists to be synthesized, and 
clinical development followed for conditions such as depression, obesity, addiction, 
schizophrenia (see Table 1, and Cryan and Lucki 2000; Fletcher et al. 2002a; 2002b; 
2004; 2008; 2001; 2012; Kennett et al. 1994; 1996; 2000; Grottick et al. 2000; 2001; 
2015; Lee and Meltzer 1994; Niswender et al. 2001; Millan et al. 2003; 2005; 2008; 2011; 
Millan 2003; 2005; Miller 2005; Higgins et al. 2012;  Rauser et al.  2001; Marquis et al. 
2007; Cunningham et al.  2011; 2013; Cunningham and Anastasio 2014; Anastasio et al. 
2014a, 2014b; 2015).  
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The progress in the field has been compelling, due to major advances in molecular 
biology, the availability of selective tools and their judicious use, a lot of ‘out of the box’ 
thinking and some neglect for dogmas imposed by self-named experts. Yet, the gene 
encoding the 5-HT2CR is extraordinarily complex and it has taken quite some time to 
obtain the full sequence (see Lubbert et al. 1987; Julius et al. 1988; Saltzman et al. 1991; 
Yu et al. 1991; Milatovich et al. 1992; Stam et al. 1994). There are three splice variants of 
the 5-HT2CR: the full length receptor, and two severely truncated forms (Canton et al. 
1996; Xie et al. 1996; Liu et al. 1999; Wang et al. 2000; Kishore and Stamm 2006; 
Kishore et al. 2010; Shen et al. 2013; Bombail et al. 2014), thought to be inactive, 
although they may serve as chaperones and seem to affected in disease (Dracheva et al.  
2003; 2008a; Flomen et al. 2004; Martin et al. 2013).  
5-HT2C Receptor mRNA Editing. 
Quite exceptionally for a GPCR, the primary transcript of the 5-HT2CR is subjected to 
multiple RNA editing (Burns et al. 1997; Niswender et al. 1999; 2001; Rueter et al. 1999; 
Fitzgerald et al. 1999; see also Dracheva et al. 2003; 2008a; 2008b; 2009; Camel et al. 
2012; Du et al. 2006; 2007; Di Narzo et al 2014; 2015). So far editing is only known for 
ionotropic glutamate AMPA receptors. In rodents, there are four editing sites within the 
coding region of the 5-HT2CR, whereas in humans a fifth editing site is present. Together 
they may produce up to 32 different mRNAs and 24 different proteins. The 5-HT2CR is 
characterized by constitutive activity, the level of which decreases as editing increases 
(Herrick Davis et al. 1999). For instance, RNA encoding the human 5-HT2CR undergoes 
adenosine-to-inosine RNA editing at five positions, resulting in alterations of amino acids 
in the second intracellular loop. Edited 5-HT2CRs show reduced G-protein coupling 
compared to the non-edited isoform, and the fully edited variants (VSV and VGV) show 
lowest levels of constitutive activity and the unedited form (INI) the highest level. Editing 
also leads to a loss of the active state of the receptor (Niswender et al. 1999) and a delay 
in agonist-stimulated calcium release in the fully edited isoforms (Price and Sanders 
Bush, 2001). The unedited receptor couples to both Gq/11 and G13, whereas editing 
reduces or eliminates coupling to G13 (Price et al. 2001). Thus, editing may serve to stop 
constitutive activity by reducing coupling to G proteins. The multiple editing and some 
splice variants of the 5-HT2C receptor are probably not discriminated by antagonist 
radioligands used in binding/ autoradiographic studies; however, agonist binding such as 
[3H]5-HT, will only label receptors in an active state which depends much on the levels of 
editing. 
5-HT2C Receptor KO And Knock Down, Transgenic Models: 
5-HT2CR-KO or -mutated mice show hyperphagia, late-onset obesity, insulin resistance, 
and type 2 diabetes (Tecott et al. 1995;  Heisler et al. 1998; Nonogaki et al. 1998;  Tecott 
and Abdallah 2003;  Wade et al. 2008).  Interestingly, fenfluramine has reduced satiating 
effects in 5-HT2CR KO mice (Vickers et al.  1999), suggesting a major role for the 5-HT2C 
receptor in the reduced food intake produced by fenfluramine, norfenfluramine, benfluorex 
and possible effects on insulin/diabetes of these drugs (Wade et al.  1998). 5-HT2CR-KO 
or -mutated mice also have spontaneous and audio-induced seizures (Brennan et al. 
1997; Heisler et al. 1998; 2002) and show locomotor hyperactivity via 5-HT1BR (Heisler 
and Tecott 2000; Rocha et al. 2002). The 5-HT2CR knock down produces motor 
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impulsivity and increased cocaine sensitivity (Anastasio et al., 2015), that may result from 
an imbalance with the 5-HT2A receptor in the medial prefrontal cortex.  Further evidence 
from KO mice and other models suggest a role for the 5-HT2C receptors in 
neuroendocrine responses to stress and an anxiolytic phenotype (Rocha et al. 1993; 
1994; Heisler et al. 2007a; 2007b). Interestingly, the effects of 5-HT uptake blockade are 
reinforced in 5-HT2CR KO mice (Cremers et al. 2004). 5-HT2CR-selective expression in 
POMC neurons of 5-HT2CR KO mice (Xu et al. 2008; 2010) reverses hyperphagia and 
restores insulin levels. These studies have been instrumental in directing the preclinical 
and clinical development of a number of drug candidates, and eventually some clinical 
translation, although much more work is in progress, especially in the addiction field (see 
below). 
5-HT2C Receptor Homomers And Heteromers. 
Several members of the 5-HT receptor family, including the 5-HT2CR, have been reported 
to form homodimers (see Herrick-Davis 2013, for a review). 5-HT2CR homodimer 
formation occurs in the endoplasmic reticulum during receptor biosynthesis (Herrick-Davis 
et al. 2006) and the dimer is then transported through the Golgi complex to the plasma 
membrane. 5-HT2CR homodimers do not form higher order complexes (tetramers or 
higher) following agonist or inverse agonist treatment (Herrick-Davis et al. 2004; 2007; 
2012). The 5-HT2CR homodimer interacts with a single G protein, with both active 
protomers needed for signaling to occur (Herrick-Davis et al. 2005). Homodimerization 
occurs with both the unedited INI and the fully edited (VSV and VGV) isoforms (Herrick-
Davis et al. 2007; 2012). Heterodimers can form between the different editing isoforms of 
the 5-HT2CR.  In HEK293 cells, INI/VSV, INI/VGV and VSV/VGV isoform pairs have been 
reported (Herrick-Davis and Farrington 2011). The native choroid plexus 5-HT2CR is 
expressed as homodimers on the apical surface of the epithelial cells (Herrick-Davis et al. 
2015). 
Heterodimers between the 5-HT2CR and the 5-HT2AR are likely to exist, but have not been 
demonstrated, although 5-HT2AR and 5-HT2CR protein co-localize in rat medial prefrontal 
cortex (Anastasio et al., 2015). Furthermore, combination 5-HT2A antagonist / 5-HT2C 
agonist seem to act in synergy, which support the claim by Cunningham’s group to 
develop dual compounds for the treatment of various forms of addiction. Thus, 
subthreshold doses of the 5-HT2AR antagonist M100907 combined with the selective 5-
HT2CR agonist WAY163909 synergistically suppressed cocaine-evoked motor impulsivity, 
hyperactivity and cocaine-seeking behavior (Cunningham et al. 2013).  
The 5-HT2CR and ghrelin receptor appear to form heterodimers when overexpressed in 
HEK293 cells. Further, the two receptors colocalize in cultured primary rat hypothalamic 
and hippocampal neurons (Schellekens et al., 2015). Interestingly, activation and 
blockade of 5-HT2CR in vivo attenuated and potentiated, respectively, the orexigenic 
effects of ghrelin. It remains to be seen whether compounds such as fenfluramine, 
norfenfluramine or benfluorex act primarily on these receptor heterodimers or 
preferentially on 5-HT2CR homodimers. 
The formation of 5-HT2CR and melatonin MT2R heterodimers has been reported in 
transfected cells, and importantly human cortex and hippocampus (Kamal et al., 2015). 
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The antidepressant / anxiolytic agomelatine displays 5-HT2CR antagonist and MT1 and 
MT2 receptor agonist properties. Whether the receptor heterodimer is the target of 
agomelatine and other antidepressants / anxiolytics remains to investigated. 
The glutamate N-Methyl-D-aspartate (NMDA) receptor subunit GluN2A co-localizes with 
the 5-HT2CR in rat spinal cord neurons and synaptosomal fractions (Bigford et al., 2012). 
5-HT2CR activation enhanced NMDA-evoked motoneuron depolarization (Bigford et al., 
2012), suggesting the existence of 5-HT2CR / NMDA hetero complex in the spinal cord. 
THE MODERN ERA:  THERAPEUTIC CONSIDERATIONS. 
The clinical relevance of 5-HT2CR editing has been linked in genome wide association 
studies (GWAS), animal models or clinical samples,  to suicidality (Niswender et al. 2001), 
schizophrenia (Sodhi et al. 2001; 2005; Reynolds et al. 2003; 2005; Zhu et al. 2012), 
anxiety (Hackler et al. 2006; 2007; Heisler et al. 2007b), depression (Iwamoto and Kato 
2003; Yang et al. 2004; Iwamoto et al. 2005; 2011), spatial memory  (Du et al. 2007), 
obesity (Yuan et al. 2000; Pooley et al. 2004), antipsychotic-induced weight gain (AIWG) 
(Basile et al. 2002; Tsai et al. 2002; Templeman et al. 2005; Wallace et al. 2011), 
addiction or impulsivity (Rocha et al. 2002; Filip and Cunningham 2002;  Winstantley et al. 
2004; Anastasio et al. 2014a), although it is fair to say that replication failure is frequent 
and contradictory data are not uncommon in GWAS. 5-HT2C receptors have been shown 
to modulate mesolimbic dopaminergic function, where they exert a tonic inhibitory 
influence over dopamine neurotransmission (Bubar and Cunningham 2007; Bubar et al. 
2011). Therefore, the interest in this receptor as a therapeutic target for treating 
substance abuse (Bubar and Cunningham 2006; 2008). The 5-HT2CR is also believed to 
mediate the effects of antidepressants, e.g. mirtazapine or agomelatine (Cremers et al. 
2004; 2007; see Millan 2003), possibly by stimulating neurogenesis, as well as that of 
atypical antipsychotics (Berg et al. 1999; Herrick Davis et al. 2000). 5-HT2CR are 
expressed in the amygdala, and fMRI data have demonstrated that 5-HT2CR agonists lead 
to its neuronal activation (Hackler et al. 2007). Other therapeutic indications relate to 
obesity and possibly epilepsy (Tecott et al. 1995; Brennan et al. 1997; Heisler et al. 1998; 
2007a; Tecott and Abdallah 2003) as observed in the first series of receptor transgenic 
mice and later with 5-HT2CR selective ligands (Venzi et al. 2016; Bagdy et al. 2007; Jakus 
et al.  2003; Isaac 2005).  It is still a challenge to synthesise 5-HT2CR selective agonists, 
devoid of significant interactions with the other 5-HT2 receptor subtypes, since 5-HT2B 
receptor activation results in detrimental cardiac effects such as valvulopathies (see 
Fitzgerald et al. 2000; Roth 2007), whereas 5-HT2AR activation leads to hallucinations 
(Nichols 2004).  
Depression And Anxiety: Agomelatine And Others. 
Agomelatine (Valdoxan , Melitor , Thymanax ), a selective 5-HT2CR antagonist and 
melatonin1/2R agonist, was approved by the EMA and in other countries (but not FDA), for 
the treatment of major depressive disorders.  It has also been considered in the treatment 
of sleep disorder, generalized anxiety disorders and adjunctive therapy in obsessive 
compulsive disorders. The recommended dose is 25 mg to be taken at bedtime, the dose 
may be doubled after 2 weeks if efficacy is lacking. There are some safety issues since 
liver enzymes are increased in a significant number of patients, although the compound is 
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generally well tolerated. Thus, the 5-HT2CR is involved in the serotonergic regulation of 
generalized anxiety, depression and possibly bipolar disorders. It has been known for 
some time that mCPP and MK212 induce anxiogenic-like behaviours in rodents (Kennett 
et al. 1989; Benjamin et al. 1990; Shepherd et al. 1994; Bilkei-Gorzo et al., 1998; Millan 
2003; 2005; Martin et al. 1998;  Di Giovanni et al. 2001) and these compounds have been 
used as tools to induce anxiety and panic in humans (Lowy and Meltzer 1988; Kahn and 
Wetzler 1991; Sevy et al. 1994; Southwick et al., 1997; Gatch 2003). The anxiogenic 
effects are likely due to the activation of the 5-HT2CR. 5-HT2CR knockout mice exhibit an 
anxiolytic-like phenotype (Heisler and Tecott 2000; Heisler et al. 2007b). Moreover, 
desensitization of the 5-HT2CR in SERT KO mice reduces the anxiety phenotype (Martin 
et al. 2015) and show antidepressant-like effects (Prisco and Esposito, 1995; Di Giovanni 
et al. 2006). The situation is however more complex: although, mCPP induces anxiety in 
mice (Kennett et al. 1989; Nic Dhonnchadha et al. 2003), it has antidepressant-like 
properties in the anhedonia model in rats (Moreau et al. 1996) and is apparently 
anorexigenic without inducing anxiety/depression in humans (Thomas et al. 2014). RO60-
0175, a 5-HT2CR agonist, shows antidepressant and anxiolytic/anti-compulsive like effects 
in some rodent models (Cryan and Lucki 2000; Nic Dhonnchadha et al. 2003). It seems 
that anxiogenic-like features of RO60-0175 (Martin et al. 2013; Martin et al. 2014) may be 
related to its sedative properties (Kennett et al. 2000). Yet, all compounds are not equal: 
CP809101 is not anxiogenic in some models (Siuciak et al. 2007) but anxiogenic in others 
(Strong et al. 2009; 2011; Christianson et al. 2010), suggesting that pathway selection 
may be at play.  Thus, some 5-HT2CR antagonists have strong anxiolytic/antidepressant 
properties in numerous tests (Kennett et al., 1994; 1996; 1997; 2000; Wood et al. 2001; 
Millan, 2005; Harada et al., 2006). On the other hand and surprisingly, both 5-HT2CR 
agonists and antagonists have been reported to have anxiolytic/antidepressant properties, 
in the chronic mild stress-induced anhedonia and olfactory bulbectomy models of 
depression. It has been suggested that selective 5-HT2CR agonists would be more 
appropriate to treat depression, obsessive-compulsive disorder or panic attacks, while 
antagonists would be better suited for generalized anxiety and obsessive-compulsive 
disorder (Jenck et al. 1998; Millan 2003; 2005). However, the atypical antidepressants 
mirtazapine and mianserin (Hayasaka et al. 2015) and the recently developed 
antidepressant agomelatine (Millan et al. 2003; 2011; Millan 2005) have clear antagonistic 
5-HT2CR profiles. Local activation of the 5-HT2CR in the basolateral amygdala is 
anxiogenic (Campbell and Merchant 2003), whereas 5-HT2CR activation in the dorsal 
periaqueducal grey is anxiolytic (Yamashita et al. 2011). Be it is at it may, agomelatine is 
a 5-HT2CR with additional melatonin 1 and 2 receptor agonism that has been registered 
for the treatment of major depression in Europe and a number of other countries, but not 
in the USA. Interestingly, the 5-HT2CR receptor may form heterodimers with melatonin 
receptors (Kamal et al 2015), although the functional consequences for the therapeutic 
effects of agomelatine need to be clarified.  It is clear that other antidepressants display 
potent 5-HT2CR antagonism, e.g. mirtazapine or mianserin, although their receptor profile 
is by no means selective.   
Appetite, Satiety And Obesity: Lorcaserin, Fenfluramine And Others. 
There is ample evidence that the 5-HT2CR plays a role in the management of hunger, food 
intake and satiety (Lucki 1998; Blundell 1999; Halford et al. 1997;  1998; Halford and 
Blundell 2000; Voigt and Fink, 2015).  Lorcaserin (Belviq ) is a selective, high-efficacy 5-
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HT2CR agonist (Thomsen et al. 2008; Smith et al. 2009; 2010) marketed for weight 
reduction in patients with a body-to-mass (BMI) index of >30 or with a BMI >27 comorbid 
with type-2 diabetes, hypertension or dyslipidemia (FDA (2012): 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm). The 
development of Lorcaserin was based on the knowledge accumulated with previously 
developed selective ligands such as the agonists RO60-0175 (Fletcher et al. 2004), 
WAY163909 (Dunlop et al. 2005; 2006) or the antagonist SB242084 (Bromidge et al. 
1997) and SB206553 (Kennett et al. 1996), but also from older compounds such as 
fenfluramine, dexfenfluramine, mCPP or MK212, which act as 5-HT2CR agonists and 
various antipsychotics or cyproheptadine which act as 5-HT2CR antagonists. The 5-HT 
releaser d-fenfluramine and its active metabolite d-norfenfluramine, other preferential 5-
HT2CR agonists such as mCPP or MK212, evoke hypophagia and increase satiety in 
rodents, keeping in mind that mCPP has anxiogenic effects. The effects on food intake 
are blocked by 5-HT2CR antagonists or by the constitutive 5-HT2CR KO (Kennett and 
Curzon 1988; Tecott et al. 1995; Halford et al. 1997; Vickers et al. 1999; Dalton et al. 
2006; Nonogaki et al. 1998; 2008). Selective 5-HT2CR agonists such as lorcaserin, RO60-
0175 or WAY163909 do consistently suppress food intake (Clifton et al. 2000; Hewitt et 
al.  2002; Somerville et al., 2007; Thomsen et al., 2008; Grottick et al. 2000; 2015; Higgs 
et al. 2016). Interestingly, WAY163909 decreased food intake in normal Sprague–Dawley 
rats, obese Zuker rats and diet-induced obese mice without the anxiogenic effects of 
mCPP (Dunlop et al. 2005; 2006). Constitutive 5-HT2CR knockout mice show hypophagia 
and increased body mass in the context of both insulin resistance and late-onset obesity 
(Tecott et al. 1995; Nonogaki et al. 2008). Some 5-HT2CR antagonists such as 
cyproheptadine disrupt the satiety sequence and increase appetite (Chinuck et al. 2007; 
Bergen 1964; Ishii et al. 2003). Weight gain and a greater relative risk of metabolic 
dysfunction and diabetes is associated with atypical antipsychotics with 5-HT2CR 
antagonist properties, such as clozapine and olanzapine in both patients and animals 
(Wirshing et al. 1999; DeLuca et al.  2007; Kirk et al. 2009). Thus 5-HT2CR antagonism 
may lead to highly detrimental side effects and explains in part the lack of compliance 
seen with some atypical antipsychotics. However, the situation may be somewhat more 
complex, since selective 5-HT2CR antagonists may increase (Bonhaus et al. 1997; Higgs 
et al. 2016;) or decrease food intake depending upon the rodent preclinical model 
(Kennett et al. 1997; Murotani et al. 2011; Higgs et al. 2016). What is clear however, is 
that 5-HT2CR agonism has positive effects in preclinical models of food intake and satiety, 
and that such effects may also translate positively with respect to diabetes;  keeping in 
mind that all 5-HT2CR are not equal, more specifically with respect to biased signalling. 
Thus, d-fenfluramine and RO60-0175 reduce the rate of feeding and meal size and 
increase the latency to feed (Clifton et al., 2000). The effects of d-fenfluramine are 
markedly reduced in 5-HT2CR KO mice (Vickers et al. 1999). Lorcaserin reduces the 
number of licking bouts probably by promoting satiety (Higgs et al. 2016; Davis et al. 
2001). The sites of action of lorcaserin and other selective 5-HT2CR ligands in the 
mechanisms underlying satiety are to be found in hypothalamic and midbrain/hindbrain 
circuits that modulate energy balance and glucose homeostasis in concert with the 
periphery (Gautron et al. 2015; Voigt and Fink 2015). Multiple hypothalamic nuclei 
express 5-HT2CR (van de Kar and Lorens 1979; Peyron et al. 1998; Hoffman and Mezey 
1989; Molineaux et al. 1989; Mengod et al. 1990;  Pompeiano et al. 1994). Indeed, 
arcuate nucleus POMC neurons expressing 5-HT2CR are activated by d-fenfluramine and 
mCPP (Heisler et al. 2002; Lam et al. 2008;  Xu et al.  2008; 2010), which translates into 
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the synthesis of α-MSH.  α-MSH in turn, acts on melanocortin 4 receptors in the 
hypothalamic paraventricular nucleus to promote satiety, weight loss and glucose 
regulation (Heisler et al. 2007a; Zhou et al. 2007; Xu et al. 2008; 2010; Berglund et al. 
2013). Mice with a selective 5-HT2CR KO in POMC neurons, have normal body weight, 
and are insensitive to d-fenfluramine- or mCPP-evoked hypophagia; these mice develop a 
metabolic syndrome, with hyperinsulinemia, hyperglucagonemia, hyperglycemia, and 
insulin resistance (Berglund et al. 2013). This syndrome can be reversed by re-expressing 
the 5-HT2CR in POMC neurons (Xu et al. 2008). Interestingly, female mice appear to be 
different in that respect, leading to speculation about possible sex differences in the 
prevalence of obesity (Burke et al. 2016). Another interesting interplay has been reported 
between the 5-HT2CR and the leptin system. Co-administration of mCPP and leptin results 
in an additive reduction in body weight in diet-induced obese mice (Yan et al. 2015). 5-
HT2CR KO mice show leptin-independent hyperphagia and a diabetic phenotype 
(Nonogaki et al. 1998; 2008), whereas double leptin and 5-HT2CR KO mice show a 
synergistic disruption of glucose homeostasis and a profound diabetes phenotype (Wade 
et al. 2008).  Transgenic overexpressing leptin and 5-HT2CR KO mice have a lean 
phenotype on a chow diet; by contrast, on a high fat diet, these mice become markedly 
obese (Wang and Chehab 2006). Stimulation of the 5-HT2CR activates the same POMC 
neurons activated by leptin (Qiu et al. 2007; 2010). Thus, the 5-HT and leptin systems 
may function independently, but within POMC neurons of the hypothalamus, they may 
control satiety and energy reserves in a coordinated fashion (Halford and Blundell 2000). 
Schizophrenia: Vabicaserin, Sertindole And The Others. 
Both selective 5-HT2CR agonists and antagonists have been suggested for the treatment 
of schizophrenia, however so far, the clinical outcome has been disappointing. 5-HT2CR 
antagonism may be effective in suppressing positive symptoms, while 5-HT2CR agonism 
may be correcting the negative symptoms and cognitive impairments (Wood et al. 2001; 
Rosenzweig-Lipson et al. 2007a; 2007b; 2012) with placebo like motor side effects (Di 
Giovanni et al. 2006; Di Giovanni and De Deurwaerdere 2016). The features of some 
atypical antipsychotics led to 5-HT2CR blockade as a strategy to improve the efficacy of 
dopamine antagonists in long-term treatments (Meltzer, 1999). On the other hand, one of 
the great expectations was that 5-HT2CR agonists would have antipsychotic effects 
without inducing AIWG and altering glucose homeostasis, a negative feature of a number 
of atypical antipsychotics. Further, experimental evidence suggested that 5-HT2CR 
agonism might increase the efficacy of typical and atypical antipsychotics, allowing dose-
sparing with a reduction of motor side-effects (Grauer et al. 2009). However, Vabicaserin 
a potential antipsychotic and anorectic with high agonist efficacy at the 5-HT2CR (Dunlop 
et al. 2011), although improving positive symptoms (Shen et al., 2014), did not meet the 
primary efficacy endpoints ( see ClinicalTrials, 2014:  
https://clinicaltrials.gov/ct2/show/results/NCT00563706?term=vabicaserin&rank=2). Its 
clinical development by Pfizer was terminated. On the other hand, Sertindole, (Juruena et 
al. 2011) a potent 5-HT2CR inverse agonist, and dopamine D2, α1-adrenergic receptor and 
5-HT2AR antagonist (Herrick-Davis et al. 2000; Hietala et al. 2001), was either not 
registered (USA) or withdrawn form the market (Europe), due to cardiovascular side 
effects. Sertindole was effective in reducing anxiety, improving cognition/memory and 
brain plasticity, most probably by reducing 5-HT2CR tonic activation (Hietala et al., 2001). 
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In other words, clinical data have not conclusively proven or disproven the therapeutic 
potential of 5-HT2CR modulating ligands in schizophrenia, thus the jury is still out. 
RNA Editing, Spinal Cord Injury And More:  A Case For Inverse 5-HT2C Receptor 
Agonists 
Spinal cord injury (SCI) patients suffer from paralysis of muscles innervated by motor 
neurons below the injury site. Weeks to months following injury, some restoration of motor 
neuron excitability may take place which may be associated with some recovery of motor 
function. However, that recovery is often accompanied by marked muscle spasms that 
may be spontaneous or can be triggered by various stimuli. A number of SCI studies 
(Murray et al. 2010) suggest a role for constitutive activation of the 5-HT2CR (and possibly 
5-HT2BR) in this process in both SCI patients and rodents (rats and mice) subjected to 
SCI (Fouad et al. 2010; Murray et al. 2011; Husch et al. 2012). In rats, following chronic 
SCI, electrical stimulation of the tail results in sustained muscle spasms; administration of 
a neutral 5-HT2CR antagonist does not affect these spasms, whereas the 5-HT2CR inverse 
agonists SB206553 and cyproheptadine inhibit the spasms most probably by blocking 
constitutively active 5-HT2CR. These effects can be reproduced in the isolated spinal cord 
in vitro, ruling out a role for local 5-HT in the spasms. Along these lines, chronic SCI was 
associated with a fourfold increase in expression of the unedited, constitutively active 
isoform of the 5-HT2CR. In SCI patients, leg muscle spasms evoked by cutaneous 
stimulation to the foot are significantly reduced by oral administration of cyproheptadine. 
These data suggest the use of 5-HT2CR inverse agonists (and possibly 5-HT2BR 
antagonist) to manage SCI spasticity. However, recovery of locomotion in rats following 
partial SCI was also inhibited by SB206553, implying that constitutive 5-HT2CR activity is 
needed for normal locomotion. Thus a therapeutic window is to be considered when using 
such agents.  
5-HT2CR RNA editing is not limited to SCI, a number of attempts have been made to 
relate editing to psychiatric disorders and suicide (e.g. Niswender et al. 2011; Gurevich et 
al. 2002; Lyddon et al. 2013).  It is clear that is some brain regions and depending on 
state, native 5-HT2CR display constitutive activity which can vary largely (Di Giovanni et al. 
1999; Di Matteo et al. 2000; Gobert et al. 2000; Leggio et al. 2009; Navailles et al. 2004; 
2013a; 2013b). A number of antipsychotics behave actually as inverse agonists (Berg et 
al. 1999; Herrick-Davis et al. 2000; Rauser et al. 2001; Navailles et al., 2004; Aloyo et al.  
2009; Sullivan et al; 2015) and if the 5-HT2CR is a target, their effectiveness may depend 
on the level of constitute activity of the receptor (Navailles et al. 2013b). A complicating 
factor is that constitutive activity may vary with transduction pathway (Berg et al. 1994; 
1998a; 1998b; 2001; 2008a; 2008b; Moya et al.  2007; Wang et al.  2000; Werry et al. 
2005; 2008;  Berg and Clarke 2009), receptor desensitization and trafficking may be at 
play as well (Berg et al. 1999; Marion et al., 2004) and different ligands may possess 
different pathway selectivity. In other words, the situation may be even more complex 
than ever envisaged and again the status of the receptor may well be disease- and cell-
type dependent. 
Addiction And Substance Use Disorders: Lorcaserin. 
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The role of the 5-HT2CR in various addictive processes has been amply investigated. 5-
HT2CR agonists suppress nicotine intake and nicotine-seeking in preclinical models 
(Grottick et al. 2001; Levin et al. 2011; Fletcher et al. 2012; Higgins et al. 2012) leading to 
clinical trials with lorcaserin in nicotine abuse (Eisai, 2014:  
http://www.eisai.com/news/news201465.html). The early clinical data suggest lorcaserin 
given 10 mg twice daily, to increase abstinence from nicotine modestly but significantly, 
as may be expected from preclinical studies dealing with other substance abuse 
paradigms such as cocaine and other psychostimulants, ethanol and opiates as well as 
factors involved in relapse, impulsivity and cue reactivity (Cunningham et al. 2011; 2013; 
Cunningham and Anastasio, 2014; Rezvani et al., 2014; Howell and Cunningham 2015; 
Harvey-Lewis et al. 2016). Cocaine administration elevates 5-HT in the Nucleus 
Accumbens (NAc) (Parsons and Justice 1993; Parsons et al. 1995; Howes et al. 2000). 5-
HT2CR KO mice show an increased motivation to self-administer cocaine and cocaine-
induced elevation in dopamine in the NAc (Rocha et al. 2002). A 5-HT2CR agonist, 
enhances, whereas a 5-HT2CR antagonist inhibits, the elevated dopamine efflux in the 
NAc evoked by cocaine administration (Navailles et al. 2004; 2008; Cathala et al. 2015). 
Selective 5-HT2CR agonists e.g. RO60-0175 or WAY163909 suppress voluntary intake of 
cocaine (Grottick et al. 2000; Fletcher et al. 2002a; 2004; Neisewander and Acosta 2007; 
Cunningham et al., 2011) probably via NAc dopamine increases. 5-HT2CR stimulation 
dose-dependently suppresses cocaine-evoked or exposure to cocaine-associated cues  
(Grottick et al. 2000; Neisewander and Acosta 2007; Burbassi and Cervo 2008; Fletcher 
et al. 2002a; 2004; 2008; 2011; Cunningham et al. 2011; Swinford-Jackson et al. 2016). 
Selective 5-HT2CR blockade produces opposite effects on self-administration of low doses 
of cocaine (Fletcher et al. 2002a) and enhances cocaine-evoked reinstatement of drug-
seeking in rodents (Fletcher et al. 2002a; Pelloux et al. 2012). In non-human primates, 5-
HT2CR agonism attenuated the stimulant, reinforcing and reinstatement effects of cocaine, 
which are blocked by the 5-HT2CR antagonist SB242084 (Manvich et al. 2012a; 2012b; 
Ruedi-Bettschen et al. 2015). SB242084 itself may induce modest stimulant effects in 
primates (Manvich et al. 2012a; 2012b), although this data is open for discussion (Ruedi-
Bettschen et al., 2015). The 5-HT2CR mediated inhibitory tone on cocaine reward and cue 
reactivity may originate in the medial prefrontal cortex (mPFC) as suggested by local 
administration studies (Cunningham and Anastasio 2014; Howell and Cunningham 2015; 
Di Giovanni and De Deurwaerdere 2016). The 5-HT2CR functional status in the 
orbitofrontal cortex may also be a contributor to the vulnerability of impulsive rats to 
cocaine reward and cue reactivity (Besson et al. 2013). Altogether, the data suggest that 
the functional status of the cortical 5-HT2CR system may be a mechanistic driver in the 
generation of cocaine use disorder and relapse phenomena, and abstinent cocaine users 
exhibit lower sensitivity to the effects of 5-HT2CR agonists (Lee and Meltzer 1994; 
Buydens-Branchey et al. 1997; Patkar et al. 2006; Liu et al. 2011; 2012; Anastasio et al. 
2014a). Stimulation of the 5-HT2CR is also suppressing ethanol self-administration 
(Maurel et al. 1999; Tomkins et al. 2002; Kasper et al. 2013; Rezvani et al. 2014) and 
reinstatement in rodents (Kasper et al. 2013). Further, ethanol vapor exposure leads to an 
increased corticostriatal and hypothalamic 5-HT2CR mRNA, increased 5-HT2CR protein in 
the NAc and 5-HT2CR pre-mRNA editing (Yoshimoto et al. 2012; Watanabe et al. 2014). 
The behavioral effects of d-amphetamine (O'Neill et al. 1999; Rippberger et al. 2015; 
Wohr et al. 2015), 3,4-methylenedioxymethamphetamine (MDMA) (Bankson and 
Cunningham 2002; Fletcher et al. 2002b), methamphetamine (Steed et al. 2011; Graves 
and Napier 2012), and the marijuana alkaloid 9–THC (Ji et al. 2006) can be modulated 
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by the administration of 5-HT2CR agonists, thus extending the potential therapeutic value 
of selective 5-HT2CR agonists in the treatment of substance abuse. Systemic 
administration of dexfenfluramine blocks heroin self-administration in rats (Wang et al. 
1995). Selective 5-HT2CR activation reduces opioid-induced behavioral sensitization (Wu 
et al. 2015; Zhang et al. 2016). Finally, pre-clinical data presented at the ISSR 2016 
meeting in Seattle by Kathy Cunningham’s group suggest that lorcaserin may be effective 
in alleviating oxycodone addiction in human subjects.  
CONCLUSION 
The discovery of the 5-HT2CR resulted from a good mix of experimental design and 
serendipity and excellent collaborative spirit: having at hand a number of (radio)ligands 
was essential as was the use of autoradiography that pointed to the choroid plexus. This 
is not a tissue neuroscientist in big Pharma used to work with, unless one has a dedicated 
interest in blood brain barrier. Thus seeing the high receptor expression in the brain 
attracted our attention and allowed the characterization of a binding site that was clearly 
different from what had been described previously. The pharmacological characterization 
of the then called 5-HT1C receptor, led us to rethink the nomenclature of 5-HT receptors, 
starting with the 5-HT1 receptor subfamily. This was a rather controversial subject, since 
some experts at the time barely recognized the existence of 5-HT1 receptors:  Bradley 
and colleagues limited that family to the general but rather vague concept of “5-HT1-like”.  
We had already made up our mind that subtypes of 5-HT1 receptors existed, 5-HT1A, 5-
HT1B, rapidly expanding to 5-HT1D, although the latter two were largely species variants as 
suggested in binding, 2nd messengers and functional studies across species (Hoyer and 
Middlemiss 1989), as confirmed by cloning (Hartig et al. 1996; Hoyer et al. 2002). For a 
short while we thought that the functional correlate to the 5-HT1C/2C site was the receptor 
described by John Vane in the stomach fundus, but although similar, it became evident 
following its cloning that 2C and 2B were indeed different! Many years later, (drug 
development can be a very long enterprise), it becomes clear that the original 5-HT1C site 
did make relevant contributions to modern pharmacology, not only to nomenclature. The 
development of selective 5-HT2CR selective drugs has pioneered the demonstration of the 
capability of certain ligands to differentially activate different signal transduction pathways 
(Berg et al. 1998a; 1998b; 2003):  this evidence has been instrumental for the concept of 
“ligand-dependent functional selectivity”. In addition to challenging the dogma of classical 
pharmacology, this concept has a clear impact on drug discovery (Millan et al. 2003). The 
5-HT2CR is undoubtedly one of the most complex members of the GPCR superfamily, 
given its multiple editing and splice variants, yet it is clearly the target of a number of 
drugs which may act rather differently in health and disease. The clinical development of 
agomelatine as an antidepressant as a potent 5-HT2CR antagonist and melatonin receptor 
agonist aimed at improving sleep, is a first illustration of what selective modulation of 5-
HT2CR can achieve clinically. With the marketing of the high-efficacy 5-HT2CR agonist 
lorcaserin (Belviq ) for obesity (and possibly smoking) and the active investigation of its 
potential therapeutic value for addictive disorders and epilepsy, for example, the field is 
gaining valuable information concerning the clinical opportunities for 5-HT2CR agonists. 
Some of the unwanted effects on body mass of both older and newer antipsychotics may 
be explained by their 5-HT2CR antagonism and this knowledge should help to design 
better antipsychotics devoid of massive weight gain and metabolic syndrome, which limits 
compliance for otherwise reasonably good medications. However, the situation is 
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probably more complex since not all 5-HT2CR antagonists induce weight gain (e.g. 
agomelatine). The 5-HT2CR may well be one of the two primary targets of 
fenfluramine/dexfenfluramine/benfluorex and explain their effects of weight loss, due to 5-
HT2CR agonism. Obviously, their 5-HT2BR agonism represented a major and dramatic 
“side” effect and led to their discontinuation and that of other 5-HT2BR agonists (Roth 
2007). Surprisingly, it would seem that 5-HT2CR agonism (Vabicaserin), may also be an 
approach to treat different aspects of schizophrenia, although more robust clinical data 
are needed before drawing firm conclusions. Also surprising, is the fact that both 5-HT2CR 
agonists and antagonists have been reported to have antidepressant activities in animal 
models; is this related to pathway selection, inverse agonism or disease model?  The 
complexity of the 5-HT2CR is even greater than just expected from RNA editing and 
splicing:  5-HT2CR are able to form homodimers that seem necessary for signal 
transduction and heteromers with e.g. NMDA or melatonin or ghrelin receptors (Herrick-
Davis 2013; Herrick-Davis et al. 2004; 2005; 2006; 2007; 2012; 2015; Herrick-Davis and 
Farrington 2011; Bigford et al. 2012; Kamal et al. 2015; Schellekens et al. 2015). The 
latter raise further questions about the actual target of drugs such as agomelatine or 
lorcaserin and their effects in depression or eating behaviour. 5-HT2CR as many others 
have a complex pattern of interations with multiple GIPs (GPCR interacting proteins, see 
e.g. Becamel et al. 2001; 2002; 2004; Parker et al. 2003;  Gavarini et al. 2006;  Labasque 
et al. 2008; Maillet et al. 2008; Kleene et al. 2015). Finally, 5-HT2CR antagonists (or at 
least inverse agonists), may help in controlling involuntary movements / muscle spasms 
that result from a marked increase in constitutive 5-HT2CR activity in spinal cord injury 
patients. Future studies are still required to further untangle the complexities of 5-HT2CR 
signalling, RNA editing and the neuronal mediators which regulate behaviour and 
physiology through this fascinating receptor that was first seen in the choroid plexus: “2C 
is to believe”. 
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TABLE 1:  Important preclinical and clinical developments in and around the 5-HT2C 








1948  Synthesis of 5-HT Rapport, 1948 
1957 5-HTM and D receptors in guinea pig ileum Gaddum and Picarelli, 1957 
1978  Concept of neuroleptic receptor Leysen et al. 1978 
1979 Concept of 5-HT1 and 5-HT2 sites in brain Peroutka and Snyder, 1979 
1981 5-HT1A and 5-HT1B binding Pedigo et al. 1981 
1982- 8-OH-DPAT, a selective 5-HT1A agonist and radioligand HJjorth et al. 1982; Middlemiss and 
Fozard, 1983; Gozlan et al. 1983 
1983 [3H]Mesulergine, a dopaminergic ligand labels 5-HT2 sites Closse, 1983 
1984- The choroid plexus receptor defined as 5-HT1C receptor 
using [3H]mesulergine, [3H]5-HT, [125I]LSD  and 
[125I]SCH23982 
Pazos et al. 1984a; 1984b; Hoyer et 
al. 1985a; 1985b; Yagaloff and Hartig; 
1985; 1986; Hoyer and Karpf, 1988 
1985 Full characterization of 5-HT1A, 1B, 1C receptors (species 
differences, no 5-HT1B in pig brain), comparative 
distribution of 5-HT1/5-HT2 sites in rodent brain 
Hoyer et al. 1985a, 1985b; Pazos and 
Palacios, 1985; Pazos et al. 1985 
1986- Distribution of 5-HT1 and 5-HT2 receptors in the brain 
(species differences, no 5-HT1B sites in human brain) 
Hoyer et al. 1986a; 1986b 
 Cloning of the beta2 adrenoceptor and 5-HT1A receptor 
(the orphan G21) 
Dixon et al. 1986; Fargin et al. 1988 
 5-HT1C couples to PLC activity, does not couple to cAMP 
production 
Conn et al. 1986;  Palacios et al. 
1986, Hoyer et al. 1989 
1987 Partial cloning of 5-HT1C receptor Lubbert et al. 1987 
1988- 5-HT1C and 5-HT2 receptors proposed to belong to same 
family based on pharmacological/operational  and 2nd 
messengers/transductional criteria 
Hoyer 1988a, 1988b 
 Full length cloning of 5-HT1C and 5-HT2 receptors Julius et al. 1988; Pritchett et al. 
1988; Saltzmann et al. 1991; Xie et al. 
1996 
 5-HT1D site identified in non-rodent brain  Hoyer et al.1988; Waeber et al. 1988; 
Hoyer et al. 1988 
1989- Structural similarities between 5-HT2A and 5-HT1C 
receptors 
Julius et al. 1989; Foguet et al. 1992b 
 In situ hybridization of 5-HT1CR mRNA in brain Hofman and Mezey 1989; Mengod et 
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al. 1990; Palacios et al. 1990; 
Pompeiano et al. 1994; Lopez-
Gimenez et al. 2001; Serrats et al. 
2005; Mengod et al. 2010 
 5-HT1B and 5-HT1D receptors may be species 
homologues? 
Hoyer and Middlemiss, 1989 
1992 Structural similarities between the 5-HT2F receptor 
(fundus) and 5-HT2 and 5-HT1C 
Foguet et al. 1992b; Lubbert et al. 
1992   
1993- New nomenclature proposal for 5-HT receptors: 5-HT1C 
becomes 5-HT2C, 5-HT2 = 5-HT2A, 5-HT2F =5-HT2B,  7 
families are recognised 
Humphrey et al. 1993 
 Role of 5-HT2C receptors in the amygdala / fear / aversion 
/ anxiety / depression 
Rocha et al. 1993; 1994; Cryan and 
Lucki, 2000; Millan, 2003; 2005; 
Rosenzweig Lipson et al. 2007b 
1994 Official IUPHAR nomenclature 5-HT receptors Hoyer et al. 1994 
1995- 5-HT2CR KO mice show feeding / metabolic defects, 
hyperphagia, late-onset obesity, insulin resistance, type 2 
diabetes, epileptic seizures, an addiction phenotype, 
locomotor hyperactivity, neuroendocrine response to 
stress, anxiolytic phenotype. 
Tecott et al. 1995; Brennan et al. 
1997; Nonogaki et al. 1998; Vickers et 
al. 1999; Heisler and Tecott 2000; 
Tecott and Abdallah, 2003; Heisler et 
al., 2007a; 2007b; Wade et al. 2008; 
Tecott et al. 2005; Xu et al. 2008; 
2010 
 Synthesis of selective 5-HT2CR antagonists, inverse 
agonists: SDZ SER082, SB 206553; SB-242084, RS-
102221, SB2 43213, FR260010, 
Nozulak et al. 1995; Kenneth et al. 
1996; Bromidge et al. 1997; Bonhaus 
et al. 1997;  Wood et al. 2001; Harada 
et al. 2006. 
 Brain distribution of 5-HT2CR using Antibodies Abramowski et al. 1995 
1996- 5-HT receptors aligned to human genome, 5-HT1Dalpha/beta 
become 5-HT1B and 5-HT1D 
Hartig et al. 1996; Hoyer and Martin, 
1997 
1997- 5-HT2CR is unique amongst GPCRs and subjected to 
multiple RNA editing. The unedited INI and the fully edited 
(VSV and VGV) isoforms show high and low constitutive 
activity. 
Burns et al. 1997; Niswender et al. 
1999; 2001; Rueter et al. 1999; 
Fitzgerald et al. 1999; see also 
Dracheva et al. 2003; 2008a; 2008b; 
2009; Camel et al. 2012; Du et al. 
2006; 2007; Di Narzo et al 2014; 2015 
1999- Many antipsychotics are 5-HT2CR inverse agonists/ 
antagonists. May explain obesity produced by 
antipsychotics. 
Berg et al. 1999; Sullivan et al. 2015; 
Tsai et al. 2002; Templeman et al. 
2005; Wallace et al. 2011 
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 The 5-HT2BR is responsible for valvulopathies induced by 
agonists: fenfluramine, norfenfluramine, valproex, MDMA. 
5-HT2BR agonists are withdrawn from the market 
(fenfluramine, norfenfluramine, cabergoline, pergolide, 
valproex). Strict limitations for the development of 5-HT2R 
agonists. 
Rothmann et al. 2000;  Setola et al. 
2003; Roth, 2007; Huang et al. 2009; 
Rothmann and Baumann, 2009a, 
2009b 
2002- 5-HT2CR agonism in nicotine, cocaine and alcohol 
addiction 
 
Rocha et al. 2002; Filip and 
Cunningham, 2002; Tomkins et al. 
2002; Bubar and Cunningham, 2006; 
2007; 2008; Cunningham et al. 2011;  
2013; 2014; Liu et al. 2011; 2012; 
Levin et al. 2011; Higgins et al. 2012; 
Rezvani et al. 2014; Anastasio et al. 
2014, 2015 
2003- Agomelatine, the first 5-HT2CR antagonist / melatonin R 
agonist in development for major depressive disorders  
Millan et al. 2003; Millan, 2005; Millan 
et al. 2005;  
2004- 5-HT2CR Homomers, dimers; 5-HT2C R/NMDAR 
heteromer;  5-HT2CR /ghrelin receptor heteromer;  5-
HT2CR/melatonin MT2R heteromer  
Herrick-Davis et al. 2004, 2006, 2011, 
2012, 2013; Bigford et al., 2012; 
Schellenkens et al. 2015; Kamal et al. 
2015 
2005- Agomelatine: submission to EMEA for major depressive 
disorders; EMEA rejects agomelatine. 
See EMEA/37021/2007  
2005- Discovery of 5-HT2CR Agonists: WAY-163909; 
Vabicaserin (SCA136), Lorcaserin (APD356) 
Dunlop et al. 2005; 2011; Thomsen et 
al. 2008 
2007- 5-HT2CR agonist vabicaserin (Pfizer);  inverse agonists 
e.g. Sertindole;  Development in schizophrenia 
Siuciak et al. 2007; Dunlop et al. 
2006; Rosenzweig-Lipson 2007a, 
2012; Shen et al. 2014 
2008- Lorcaserin submitted to FDA for obesity 
 
Thomsen et al. 2008; Smith et al. 
2009; 2010; Higgs et al. 2016 
2009 EMEA approves agomelatine as Valdoxan , Melitor , 
Thymanax  by Servier. 
See EMA/633676/2014 (valdoxan),   
see EMA/695134/2016 (Thymanax) 
2010- 5-HT2C receptors in spinal cord injury, increased editing 
and constitutive activity, role in muscle spasms 
Murray et al. 2010; Fouad et al. 2010; 
Murray et al. 2011; Husch et al. 2012 
2012  FDA approves Lorcaserin for the treatment of certain 
forms of obesity as Belviq ,  co-development between 
Arena and Eisai. 





2013-  Regular IUPHAR receptor Nomenclature updates in BJP Alexander et al. 2013; 2015 
 Crystal structure of 5-HT1B and 5-HT2B receptors reveals 
striking similarities in orthosteric binding sites, yet 
profound pharmacological differences. 
Wacker et al. 2013; Wang et al. 2013; 
McCorvy and Roth, 2015 
2014 Lorcaserin is active in nicotine addiction See Eisai (2014)  
 Development of vabicaserin in schizophrenia is stopped 
by Pfizer  
See GovtTrials (2014) 
2016 5-HT2CR agonism effective in oxycodone abuse (rodents) Cunningham et al. 2016 
